Management of von Willebrand disease in developing countries

Seminars in Thrombosis and Hemostasis

Volumn 31, Issue 5, 2005, Pages 602-609

  Mannucci, Pier M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cryoprecipitate; DDAVP; Desmopressin; Developing countries; Factor VIII concentrates; Treatment; Von willebrand disease

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BIOSTATE; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; CONFACT F; DESMOPRESSIN; EMOCLOT; ESTROGEN; FACTOR 8 Y; FANHDI; FRESH FROZEN PLASMA; GESTAGEN; HAEMOCTIN; HAEMOSOLVATE; HEMORAAS; HORMONE; IMMUNOGLOBULIN; KOATE DVI; OCTANATE; TRANEXAMIC ACID; VON WILLEBRAND FACTOR; WILFACTIN;

CONTROLLED STUDY; DEVELOPING COUNTRY; DRUG SAFETY; ECONOMIC ASPECT; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; REVIEW; VIRUS INACTIVATION; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASE TYPE 1; VON WILLEBRAND DISEASE TYPE 2; VON WILLEBRAND DISEASE TYPE 3;

BLOOD COAGULATION FACTORS; CHEMOTHERAPY, ADJUVANT; DEAMINO ARGININE VASOPRESSIN; DEVELOPING COUNTRIES; DISEASE MANAGEMENT; HEMORRHAGE; HUMANS; PRACTICE GUIDELINES; TREATMENT OUTCOME; VON WILLEBRAND DISEASE;

EID: 27844538748     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-922231     Document Type: Review

References (47)

1. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160-174
2. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987;69:454-459
3. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993;123:893-898
4. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998;67:395-424
5. Kaufmann JE, Oksche A, Wollheim CB, Günther G, Rosenthal W, Vischer UM. Vasopressin induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 2000;106:107-116
6. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975;30:81-93
7. Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand disease. Br J Haematol 1981;47:283-293
8. Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996;76:692-696
9. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio AM. Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand disease. Lancet 1977;1:869-872
10. Rodeghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood 1989;74:1997-2000
11. Mannucci PM, Lombardi R, Bader R, et al. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood 1985;66:796-802
12. Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood 1982;59:1272-1278
13. Mazurier C, Gaucher C, Jorieux S, Goudemand M, Collaborative Group. Biological effect of desmopressin in eight patients with type 2 N ('Normandy') von Willebrand disease. Br J Haematol 1994;88:849-854
14. Mannucci PM, Lombardi R, Castaman G, et al. von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers. Blood 1988;71:65-70
15. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with hemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992;82:87-93
16. Smith TJ, Gill JC, Ambroso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989;31:199-202
17. Bond L, Bevin D. Myocardial infarction in a patient with hemophilia A treated with DDAVP. N Engl J Med 1988;318:121 (letter)
18. Byrnes JJ, Larcada A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988;28:63-65
19. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826-831
20. Perkins HA. Correction of the hemostatic defects in von Willebrand disease. Blood 1967;30:375-380
21. Rodeghiero F, Castaman G, Meyer D, Mannucci PM. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang 1992;62:193-199
22. Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P® in von Willebrand disease. Haemophilia 1998;4:33-39
23. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002;87:224-230
24. Mannucci PM, Chediak J, Hanna W, et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002;99:450-456
25. Kohler M, Hellstern P, Wenzel E. The use of heat-treated factor VIII concentrates in von Willebrand's disease. Blut 1985;50:25-27
26. Mazurier C, De Romeuf C, Parquet-Gernez A, Goudernand M. In vitro and in vivo characterization of a high-purity, solvent detergent treated factor VIII concentrate: evidence of its therapeutic efficacy in von Willebrand disease. Eur J Haematol 1989;43:7-14
27. Pasi KJ, William MD, Enayat MS, Hill FGH. Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat treated factor VIII concentrate (BPL 8Y). Br J Haematol 1990;75:228-233
28. Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III. Ann Hematol 1992;65:253-259
29. Hanna WT, Bona RD, Zimmerman CE, Carta CA, Hebert GZ, Rickles FR. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease. Thromb Haemost 1994;71:173-179
30. Goudernand J, Negrier C, Ounnoughene O, Sultan Y. Clinical management of patients with von Willebrand disease with a VHP VWF concentrate: the French experience. Haemophilia 1998;4:48-53
31. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339:245-253
32. Ruggeri ZM, Mannucci PM, Bader R, Barbui T. Factor VIII-related properties in platelets from patients with von Willebrand's disease. J Lab Clin Med 1978;91:132-140
33. Castillo R, Monteagudo J, Escolar G, Ordinas A, Magallon M, Martin Villar J. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease. Blood 1991;77:1901-1905
34. Mannucci PM, Meyer D, Ruggeri ZM, Koutts J, Ciavarella N, Lavergne JM. Precipitating antibodies in von Willebrand's disease. Nature 1976;262:141-142
35. Mannucci PM, Federici AB. Antibodies to von Willebrand factor in von Willebrand disease. In: Aledort LM, Hoyer LW, Lusher JM, et al, eds. Inhibitors to Coagulation Factors. New York: Plenum Press; 1995:87-92
36. Mannucci PM, Tamaro G, Narchi G, et al. Lifethreatening reaction to FVIII concentrate in a patient with severe vWD and alloantibodies to vWF. Eur J Haematol 1987;39:467-470
37. Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reaction in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 1995;125:348-355
38. Ciavarella N, Schiavoni M, Valenzano E, et al. Use of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis 1996;26(suppl 1):150-154
39. Grossmann RE, Geisen U, Schwender S, Keller F. Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor. Thromb Haemost 2000;83:633-634
40. Boyer-Neumann C, Dreyfus M, Wolf M, Veyradier A, Meyer D. Multitherapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease. J Thromb Haemost 2003;1:190-192
41. Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000;84:345-349
42. (erratum Thromb Haemost, 2000;84:345-349
43. Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998;92:2707-2711
44. Pareti FI, Lattuada A, Bressi C, et al. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000;102:1290-1295
45. Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003;349:343-349
46. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002;88:378-379
47. Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 2002;88:387-388